Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, ...

Pfizer raised its full-year profit forecast on Tuesday after topping Wall Street expectations for second-quarter results as ...

Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...

European shares were higher today. The eurozone's STOXX 600 rose 0.5%, while Spain's IBEX 35 Index surged 0.2%. London's FTSE ...

Pfizer expects full-year earnings in the range of $2.90 to $3.10 per share, with revenue in the range of $61 billion to $64 billion. This story was generated by Automated Insights ( ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Intervention/Treatment: The study tested PF-07275315, an experimental drug administered as a single intravenous infusion. The purpose was to evaluate its safety profile and how it behaves in the body ...